Skip to main content

Table 3 Psychiatrist-reported impairment in QoL and different areas of functioning

From: Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey

 

Overall

US

France

Spain

Japan

China

LAI

Non-LAI

LAI

Non-LAI

LAI

Non-LAI

LAI

Non-LAI

LAI

Non-LAI

LAI

Non-LAI

Number of patients

1132

3105

251

884

335

451

410

392

84

434

52

944

QoL

***

 

**

     

*

   

  No impairment, n (%)

85 (7.5)

295 (9.5)

9 (3.6)

60 (6.8)

24 (7.2)

22 (4.9)

39 (9.5)

28 (7.1)

8 (9.5)

37 (8.5)

5 (9.6)

148 (15.7)

  Mild, n (%)

336 (29.7)

1318 (42.5)

74 (29.5)

322 (36.4)

73 (21.8)

144 (31.9)

135 (32.9)

161 (41.1)

28 (33.3)

202 (46.5)

26 (50.0)

489 (51.8)

  Moderate, n (%)

526 (46.5)

1150 (37.0)

121 (48.2)

364 (41.2)

178 (53.1)

207 (45.9)

172 (42.0)

164 (41.8)

36 (42.9)

166 (38.3)

19 (36.5)

249 (26.4)

  Severe, n (%)

172 (15.2)

298 (9.6)

42 (16.7)

112 (12.7)

59 (17.6)

73 (16.2)

58 (14.2)

32 (8.2)

11 (13.1)

26 (6.0)

2 (3.9)

55 (5.8)

  Very severe, n (%)

13 (1.2)

44 (1.4)

5 (2.0)

26 (2.9)

1 (0.3)

5 (1.1)

6 (1.5)

7 (1.8)

1 (1.2)

3 (0.7)

0 (0.0)

3 (0.3)

Social function

***

(n=3104)

**

        

(n=943)

  No impairment, n (%)

76 (6.7)

222 (7.2)

13 (5.2)

55 (6.2)

22 (6.6)

15 (3.3)

34 (8.3)

28 (7.1)

3 (3.6)

32 (7.4)

4 (7.7)

92 (9.8)

  Mild, n (%)

310 (27.4)

1120 (36.1)

55 (21.9)

254 (28.7)

65 (19.4)

115 (25.5)

126 (30.7)

132 (33.7)

37 (44.1)

171 (39.4)

27 (51.9)

448 (47.5)

  Moderate, n (%)

460 (40.6)

1220 (39.3)

108 (43.0)

383 (43.3)

158 (47.2)

192 (42.6)

153 (37.3)

150 (38.3)

26 (31.0)

189 (43.6)

15 (28.9)

306 (32.5)

  Severe, n (%)

254 (22.4)

484 (15.6)

69 (27.5)

170 (19.2)

83 (24.8)

119 (26.4)

81 (19.8)

69 (17.6)

15 (17.9)

37 (8.5)

6 (11.5)

89 (9.4)

  Very severe, n (%)

32 (2.8)

58 (1.9)

6 (2.4)

22 (2.5)

7 (2.1)

10 (2.2)

16 (3.9)

13 (3.3)

3 (3.6)

5 (1.2)

0 (0.0)

8 (0.9)

Cognitive function

****

 

**

   

*

     

  No impairment, n (%)

154 (13.6)

438 (14.1)

26 (10.4)

125 (14.1)

30 (9.0)

35 (7.8)

72 (17.6)

81 (20.7)

17 (20.2)

77 (17.7)

9 (17.3)

120 (12.7)

  Mild, n (%)

414 (36.6)

1489 (48)

93 (37.1)

407 (46.0)

105 (31.3)

159 (35.3)

154 (37.6)

159 (40.6)

33 (39.3)

197 (45.4)

29 (55.8)

567 (60.1)

  Moderate, n (%)

421 (37.2)

959 (30.9)

102 (40.6)

291 (32.9)

143 (42.7)

189 (41.9)

134 (32.7)

124 (31.6)

29 (34.5)

143 (33.0)

13 (25.0)

212 (22.5)

  Severe, n (%)

133 (11.8)

199 (6.4)

28 (11.2)

53 (6.0)

55 (16.4)

64 (14.2)

44 (10.7)

26 (6.6)

5 (6.0)

15 3.5)

1 (1.9)

41 (4.4)

  Very severe, n (%)

10 (0.9)

20 (0.6)

2 (0.8)

8 (0.9)

2 (0.6)

4 (0.9)

6 (1.5)

2 (0.5)

0 (0.0)

2 (0.5)

0 (0.0)

4 (0.4)

Ability to meet own basic needs

  

**

   

*

     

  No impairment, n (%)

242 (21.4)

732 (23.6)

49 (19.5)

201 (22.7)

62 (18.5)

109 (24.2)

116 (28.3)

125 (31.9)

10 (11.9)

58 (13.4)

5 (9.6)

239 (25.3)

  Mild, n (%)

422 (37.3)

1364 (43.9)

84 (33.5)

369 (41.7)

126 (37.6)

160 (35.5)

141 (34.4)

153 (39.0)

38 (45.2)

218 (50.2)

33 (63.5)

464 (49.2)

  Moderate, n (%)

361 (31.9)

793 (25.5)

90 (35.9)

242 (27.4)

108 (32.2)

130 (28.8)

118 (28.8)

92 (23.5)

32 (38.1)

132 (30.4)

13 (25.0)

197 (20.9)

  Severe, n (%)

97 (8.6)

192 (6.2)

25 (10.0)

59 (6.7)

35 (10.5)

49 (10.9)

33 (8.1)

19 (4.9)

4 (4.8)

23 (5.3)

0 (0.0)

42 (4.5)

  Very severe, n (%)

10 (0.9)

24 (0.8)

3 (1.2)

13 (1.5)

4 (1.2)

3 (0.7)

2 (0.5)

3 (0.8)

0 (0.0)

3 (0.7)

1 (1.9)

2 (0.2)

Ability to work

  

**

     

**

   

  No impairment, n (%)

71 (6.3)

294 (9.5)

7 (2.8)

76 (8.6)

17 (5.1)

24 (5.3)

41 (10.0)

44 (11.2)

3 (3.6)

30 (6.9)

3 (5.8)

120 (12.7)

  Mild, n (%)

256 (22.6)

1007 (32.4)

45 (17.9)

240 (27.2)

61 (18.2)

88 (19.5)

96 (23.4)

96 (24.5)

29 (34.5)

196 (45.2)

25 (48.1)

387 (41.0)

  Moderate, n (%)

326 (28.8)

929 (29.9)

84 (33.5)

239 (27.0)

86 (25.7)

107 (23.7)

101 (24.6)

107 (27.3)

34 (40.5)

172 (39.6)

21 (40.4)

304 (32.2)

  Severe, n (%)

330 (29.2)

625 (20.1)

81 (32.3)

217 (24.6)

126 (37.6)

158 (35.0)

106 (25.9)

98 (25.0)

14 (16.7)

27 (6.2)

3 (5.8)

125 (13.2)

  Very severe, n (%)

149 (13.2)

250 (8.1)

34 (13.6)

112 (12.7)

45 (13.4)

74 (16.4)

66 (16.1)

47 (12.0)

4 (4.8)

9 (2.1)

0 (0.0)

8 (0.9)

Overall general health

 

(n=3104)

***

        

(n=943)

  No impairment, n (%)

175 (15.5)

512 (16.5)

18 (7.2)

140 (15.8)

56 (16.7)

97 (21.5)

91 (22.20)

91 (23.2)

7 (8.3)

45 (10.4)

3 (5.8)

139 (14.74)

  Mild, n (%)

456 (40.3)

1527 (49.2)

109 (43.4)

394 (44.6)

122 (36.4)

162 (35.9)

153 (37.3)

169 (43.1)

40 (47.6)

245 (56.5)

32 (61.5)

557 (59.1)

  Moderate, n (%)

415 (36.7)

909 (29.3)

98 (39.0)

296 (33.5)

138 (41.2)

155 (34.4)

132 (32.2)

113 (28.8)

31 (36.9)

128 (29.5)

16 (30.8)

217 (23.0)

  Severe, n (%)

75 (6.6)

144 (4.6)

19 (7.6)

44 (5.0)

18 (5.4)

35 (7.8)

31 (7.6)

19 (4.9)

6 (7.1)

16 (3.7)

1 (1.92)

30 (3.2)

  Very severe, n (%)

11 (1.0)

12 (0.4)

7 (2.8)

10 (1.1)

1 (0.3)

2 (0.4)

3 (0.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Overall level of function

  

**

         

  No impairment, n (%)

71 (6.3)

260 (8.4)

9 (3.6)

42 (4.8)

24 (7.2)

19 (4.2)

31 (7.6)

32 (8.2)

6 (7.1)

33 (7.6)

1 (1.9)

134 (14.2)

  Mild, n (%)

370 (32.7)

1342 (43.2)

71 (28.3)

346 (39.1)

85 (25.4)

138 (30.6)

145 (35.4)

157 (40.1)

38 (45.2)

198 (45.6)

31 (59.6)

503 (53.3)

  Moderate, n (%)

469 (41.4)

1145 (36.9)

117 (46.6)

365 (41.3)

140 (41.8)

190 (42.1)

160 (39.0)

153 (39.0)

32 (38.1)

173 (39.9)

20 (38.5)

264 (28.0)

  Severe, n (%)

203 (17.9)

306 (9.9)

53 (21.1)

107 (12.1)

84 (25.1)

94 (20.8)

60 (14.6)

39 (10.0)

6 (7.1)

26 (6.0)

0 0.0)

40 (4.2)

  Very severe, n (%)

19 (1.7)

52 (1.7)

1 (0.4)

24 (2.7)

2 (0.6)

10 (2.2)

14 (3.4)

11 (2.8)

2 (2.4)

4 (0.9)

0 (0.0)

3 (0.3)

  1. *p≤0.05; **p≤0.01; ***p≤0.0001
  2. Blank cells indicate no change in sample size from the overall number of patients presented at the outset of the table. Where sample size varies, ‘n’ number is stated
  3. LAI: long-acting injectable; QoL: quality of life; US: United States